Savara Inc
No SEC Form 4 filings for $SVRA in the last 30 days.
See all $SVRA insider activity →JPMorgan initiated coverage of Savara (SVRA) with an Overweight rating and a $12 price target, implying 146% upside from its $4.88 close. The stock has fallen 30% since December, with FDA delays and wider losses. Analysts expect approval of Molbreevi on Nov. 22 to drive the stock's performance, with sales projections starting at $2.02M this year.
Analysts made several rating changes: UBS upgraded Invesco (IVZ) to Buy with a $41 target, Raymond James initiated M&T Bank (MTB) as Outperform with a $250 target, Morgan Stanley upgraded Nexa Resources (NEXA) to Overweight, and others. KeyBanc upgraded Corteva (CTVA) to Overweight with a $17 target, Jefferies upgraded Ambiq Micro (AMBQ) to Buy with a $90 target, and Citi upgraded Flutter to Buy with a $91 target.
Citizens reiterated a Market Outperform rating and $10.00 price target for Savara (SVRA), citing a 90% approval probability for Molbreevi. The firm expects strong launch prospects and undervaluation, with a peak sales potential implying a $1.6B-$2.0B valuation. SVRA shares are at $4.65, up 35.6% over the past year.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning SVRA (Savara Inc). Coverage has skewed bullish: 3 bullish, 0 neutral, and 0 bearish.
Recent SVRA coverage spans financial news, corporate actions and regulation.
Analyst upgrade and high price target could attract buying interest, especially if FDA approval occurs.
Overweight rating may lift the biotech.
Potential upside as analyst upgrades rating and raises target.
The absence of an advisory committee meeting may reduce one source of review uncertainty, while the Aug 22 PDUFA date remains a key catalyst.
Granted formulation patents reduce ex-US competitive risk and strengthen the MOLBREEVI IP moat, but do not change near-term clinical/regulatory timelines.
AlphAI scores every news story that mentions SVRA with an AI model for sentiment and relevance, and aggregates insider trades from Savara Inc's SEC EDGAR Form 4 filings. Figures refresh continuously.
JPMorgan initiated coverage of Savara (SVRA) with an Overweight rating and a $12 price target, implying 146% upside from its $4.88 close. The stock has fallen 30% since December, with FDA delays and wider losses. Analysts expect approval of Molbreevi on Nov. 22 to drive the stock's performance, with sales projections starting at $2.02M this year.
2 min readAnalysts made several rating changes: UBS upgraded Invesco (IVZ) to Buy with a $41 target, Raymond James initiated M&T Bank (MTB) as Outperform with a $250 target, Morgan Stanley upgraded Nexa Resources (NEXA) to Overweight, and others. KeyBanc upgraded Corteva (CTVA) to Overweight with a $17 target, Jefferies upgraded Ambiq Micro (AMBQ) to Buy with a $90 target, and Citi upgraded Flutter to Buy with a $91 target.
2 min readCitizens reiterated a Market Outperform rating and $10.00 price target for Savara (SVRA), citing a 90% approval probability for Molbreevi. The firm expects strong launch prospects and undervaluation, with a peak sales potential implying a $1.6B-$2.0B valuation. SVRA shares are at $4.65, up 35.6% over the past year.
1 min readThe FDA’s August 2026 Prescription Drug User Fee Act calendar includes target action dates for multiple investigational drugs and therapies. Moderna’s mRNA-1010 has an Aug 5, 2026 PDUFA date. Gilead’s bictegravir/lenacapavir has Aug 27. Lantheus’ MK-6240 has Aug 13. Other listed PDUFA dates cover programs from Capricor, BMS, Jazz, Savara, Ultragenyx, PharmaEssentia, Regeneron, Takeda, and Priovant.
4 min readSavara Inc. (Nasdaq: SVRA) said the European Patent Office granted a patent for the liquid formulation of MOLBREEVI, covering protection in Europe through March 2041 (EP No. 4121000). It also said Australia’s patent office granted a related patent (No. 62/990,810) through March 2041. MOLBREEVI is in Phase 3 for autoimmune PAP.
3 min readLowrance David L (Chief Financial Officer) sold 394,528 shares of Savara Inc (SVRA) at $5.68 ($2.24M total) on 2026-06-22.
2 min readSavara Inc (SVRA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K Savara Inc false 0001160308 --12-31 0001160308 2026-06-04 2026-06-04 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event rep
6 min readSavara Inc. (SVRA) reported a Q1 per-share loss of $-0.15, which is wider than the FactSet estimate of a $-0.13 loss. The clinical-stage biopharmaceutical company focuses on rare respiratory diseases, with its lead program, molgramostim nebulizer solution, in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP).
3 min readSavara's first-quarter net loss has widened due to increased research and development costs. The article, sourced from Reuters via Refinitiv, is a concise report on the company's financial performance for Q1.
2 min readSavara Inc. (Nasdaq: SVRA), a biopharmaceutical company specializing in rare respiratory diseases, announced its management team will attend the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference. They will participate in a fireside chat on May 19th at the NASDAQ headquarters. A live webcast and replay will be available on the company’s corporate website for 90 days.
3 min read
